The FDA grants Fast Track designation to nipocalimab for SLE, following positive results from the phase 2b JASMINE trial.

When choosing my home for the next four years, it was Stanford’s distinct — but largely under-advertised — residential program that tipped the scale for me. Like most international Indian applicants, ...

Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Please provide your email address to receive an email when new articles are posted on . SLE-DAS remission and low disease activity discriminated between patients taking active drug vs. placebo. Both ...

Higher rates of mortality seen among patients with systemic lupus erythematosus, with disparities by sex, race and ethnicity, and region.

The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing SLE is one of the most prevalent and ...

Patients with systemic lupus erythematosus (SLE) and atrial fibrillation (AF) exhibited elevated risks of severe cardiac complications, alongside increased in-hospital mortality, costs, and length of ...